<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383251</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV231</org_study_id>
    <nct_id>NCT02383251</nct_id>
  </id_info>
  <brief_title>Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer</brief_title>
  <acronym>TAPAZ</acronym>
  <official_title>A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory&#xD;
      ovarian cancer who relapse during bevacizumab maintenance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard of treatments:&#xD;
&#xD;
        -  In Europe, advanced ovarian cancer patients are treated in first line with optimal&#xD;
           debulking surgery followed by carboplatin/paclitaxel regimen plus bevacizumab during&#xD;
           chemotherapy and as maintenance for a total à 15 months. The addition of bevacizumab is&#xD;
           a standard for the patients with residual disease.&#xD;
&#xD;
        -  The addition of bevacizumab to carboplatin/gemcitabine chemotherapy was also recently&#xD;
           approved for patients with platinum sensible relapse [Aghajanian, 2012]. The bevacizumab&#xD;
           is maintained until progression.&#xD;
&#xD;
      Rationale to use anti-angiogenic agents in early relapse:&#xD;
&#xD;
        -  The recent AURELIA trial comparing paclitaxel, topotecan or liposomal doxorubicin alone&#xD;
           versus combined to bevacizumab after early failure of the first-line with&#xD;
           carboplatin/paclitaxel revealed that targeting angiogenesis was beneficial in recurrent&#xD;
           platinum-resistant ovarian cancer [Pujade-Lauraine, 2012 and 2013], with higher&#xD;
           progression-free survival (PFS). Thus, the strategy of inhibiting angiogenesis in&#xD;
           recurrent resistant-platinum ovarian cancer is very promising.&#xD;
&#xD;
        -  The recent changes of the standard of treatment of first line and platinum-sensible&#xD;
           relapse of patients with ovarian cancer highlights the question of inhibiting&#xD;
           angiogenesis for relapse during/after bevacizumab maintenance. In this last situation,&#xD;
           the strategy of continuation of antiangiogenesis therapy, just in changing chemotherapy&#xD;
           despite recurrence, showed benefit in other types of cancer (colon, lung). In ovarian&#xD;
           cancer, no study has been performed to answer to the question. In Aurelia trial,&#xD;
           However, patients did not previously receive bevacizumab.&#xD;
&#xD;
      The choice of the best antiangiogenic agent in alternative to bevacizumab needs to be&#xD;
      assessed. Small molecular inhibitor of tyrosine-protein-kinases (TK) could be used with&#xD;
      efficacy after a first-line of antiangiogenesis treatment as it was demonstrated in renal&#xD;
      cancer [Escudier, 2011].&#xD;
&#xD;
        -  Pazopanib is an oral, potent multi-targeted small-molecule inhibitor of VEGF-receptor&#xD;
           TKs (VEGFR-1 -2 -3 PDGFR and c-KIT; it is the first targeted small molecule that it has&#xD;
           demonstrated an important activity in ovarian cancer. At ASCO 2013, the AGO-OVAR16 trial&#xD;
           of maintenance of pazopanib in first line ovarian cancer has shown a benefit in&#xD;
           progression free survival (difference of 5.6 months of median PFS in favour of pazopanib&#xD;
           compared to placebo) [Dubois, ASCO 2013 LBA5503]; in this trial, the majority of the&#xD;
           patients had few residual disease and patients did not receive bevacizumab.&#xD;
&#xD;
        -  In ovarian cancer, the standard treatment for patients relapsing during bevacizumab&#xD;
           maintenance (15 to 20% of patients) is still a mono-chemotherapy. Weekly paclitaxel is&#xD;
           one oh the most commonly used chemotherapy in this situation of early relapse. However,&#xD;
           the promising results of pazopanib in first line led to develop protocols in second-line&#xD;
           in combination with chemotherapy.&#xD;
&#xD;
      The combination of weekly paclitaxel and pazopanib is feasible and the dose proposed for&#xD;
      further phase 2 studies is pazopanib 800 mg daily and paclitaxel 65 mg/m2 at day 1, 8, 15&#xD;
      every 28 days [Tan, the oncologist 2010]. The dosage of paclitaxel was justified on results&#xD;
      from previous studies, demonstrating that co-administration of pazopanib and paclitaxel&#xD;
      increases the systemic exposure to paclitaxel. An Italian group has just closed a phase 2&#xD;
      study (MITO11) that evaluated this association among ovarian patients with early relapse. In&#xD;
      this study, patients did not receive previously bevacizumab.&#xD;
&#xD;
      Thus, pazopanib is the best molecule to be associated to chemotherapy in ovarian cancer&#xD;
      patients who early relapse after a treatment including bevacizumab.&#xD;
&#xD;
      We propose a randomized phase 2 trial to evaluate the combination of pazopanib to weekly&#xD;
      paclitaxel among patients with platine resistant relapse after treatment including&#xD;
      bevacizumab maintenance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>4 months</time_frame>
    <description>Proportion of progression or death 4 months after initiation of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time between randomization and death or last news date for patient alive at the last visit date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of woman in partial, compete or stable desease according to RECIST 1.1. criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI CTCAE v4.3 criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>tolerance of the treatment based on AE occurrence according to NCI CTCAE v4.3 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>health-related quality of life and symptomatic state will be evaluated by filing questionnaires by patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Pazopanib/Paclitaxel association</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 :&#xD;
Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.&#xD;
Then:&#xD;
Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.&#xD;
Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 :&#xD;
Paclitaxel 80mg/m2 i.v. on days 1, 8, 15&#xD;
every 28 days until progression of disease or toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg</description>
    <arm_group_label>Pazopanib/Paclitaxel association</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²</description>
    <arm_group_label>Paclitaxel alone</arm_group_label>
    <arm_group_label>Pazopanib/Paclitaxel association</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Performance status ECOG &lt; 2&#xD;
&#xD;
          3. Histological documented ovarian, tubal or peritoneum carcinoma (stage IC to IV)&#xD;
&#xD;
          4. Patient treated at least with one line of platinum-based chemotherapy who have&#xD;
             relapsed within 6 months after trhe last administration of platinum-based chemotherapy&#xD;
             and taking bevacizumab for maintenance NB: Penultimate line of chemotherapy could&#xD;
             contain chemotherapy without platinum and the last line should contain platinum-based&#xD;
             chemotherapy (followed by bevacizumab for maintenance)&#xD;
&#xD;
          5. Patients must have disease that is measurable and/or evaluable according to RECIST&#xD;
             criteria and requires chemotherapy treatment&#xD;
&#xD;
          6. Patients with liver metastasis can be included&#xD;
&#xD;
          7. Subjects must provide written informed consent prior to performance of study-specific&#xD;
             procedures or assessments and must be willing to comply with treatment and follow up.&#xD;
&#xD;
          8. Life expectancy of more than 3 months&#xD;
&#xD;
          9. Able to swallow and retain oral medication&#xD;
&#xD;
         10. Adequate organ system function like:&#xD;
&#xD;
        Total bilirubin ≤ 1.5 X ULN Alanine amino transferase (ALT) and Aspartate aminotransferase&#xD;
        (AST)c ≤ 2.5 X ULN&#xD;
&#xD;
          1. Subjects may not have had a transfusion within 7 days of screening assessment.&#xD;
&#xD;
          2. Subjects receiving anticoagulant therapy are eligible if their INR is stable and&#xD;
             within the recommended range for the desired level of anticoagulation.&#xD;
&#xD;
          3. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of&#xD;
             normal) are not permitted.&#xD;
&#xD;
          4. If UPC &lt;1, then a 24-hour urine protein must be assessed. Subjects must have a 24-hour&#xD;
             urine protein value &lt;1 g to be eligible. Use of urine dipstick for renal function&#xD;
             assessment is not acceptable. 10. Women of childbearing potential must agree to use&#xD;
             effective contraception 11. Negative serum pregnancy test (if applicable) 12.&#xD;
             Affiliated to or a beneficiary of a social security category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior malignancy over the past 5 years with the exception of in situ carcinomas of the&#xD;
             cervix or basal and squamous cell carcinoma or nonmelanoma skin cancer properly&#xD;
             treated, or all solid tumor, considered as in completed remission without relapse for&#xD;
             at least 5 years&#xD;
&#xD;
          2. Central nervous system (CNS) metastases at baseline, with the exception of those&#xD;
             subjects who have previously-treated CNS metastases (surgery ± radiotherapy) and who&#xD;
             meet both of the following criteria: a) are asymptomatic and b) have no requirement&#xD;
             for steroids or enzyme-inducing anticonvulsants of P3A4 cytochrom&#xD;
&#xD;
          3. Previous treatment with monotherapy weekly paclitaxel&#xD;
&#xD;
          4. Previous treatment with bevacizumab within three weeks before start of studt treatment&#xD;
&#xD;
          5. Patients with severe hypersensitivity to a product containing castor oil polyoxyl 35&#xD;
             or paclitaxel solvent: the Chremophor&#xD;
&#xD;
          6. Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding including, but not limited to:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Known intraluminal metastatic lesion/s with risk of bleeding&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other&#xD;
                  gastrointestinal conditions with increased risk of perforation&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment.&#xD;
&#xD;
          7. Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             investigational product including, but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of the stomach or small bowel.&#xD;
&#xD;
          8. Corrected QT interval (QTc) &gt; 450 msecs or &gt; 480 msecs for patient with block branch&#xD;
&#xD;
          9. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
               -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140&#xD;
                  mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg].&#xD;
&#xD;
         10. History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating&#xD;
             agents for at least 6 weeks are eligible&#xD;
&#xD;
         11. Major surgery or trauma within 28 days prior to first dose of investigational product&#xD;
             and/or presence of any non-healing wound, fracture, or ulcer (procedures such as&#xD;
             catheter placement not considered to be major surgery).&#xD;
&#xD;
         12. to 14: All risk of bleeding&#xD;
&#xD;
        15 Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
        could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
        study procedures. 16 Unable or unwilling to discontinue use of prohibited medications 17&#xD;
        Treatment with any of the following anti-cancer therapies:&#xD;
&#xD;
          -  radiation therapy, surgery or tumor embolization within 14 days prior to the first&#xD;
             dose of pazopanib (out of bevacizumab) OR&#xD;
&#xD;
          -  chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal&#xD;
             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the&#xD;
             first dose of pazopanib (out of bevacizumab) 18 Administration of any non-oncologic&#xD;
             investigational drug within 30 days or 5 half lives whichever is longer prior to&#xD;
             receiving the first dose of study treatment 19 Any ongoing toxicity from prior&#xD;
             anti-cancer therapy that is &gt;Grade 1 and/or that is progressing in severity, except&#xD;
             alopecia. 20 Patient deprived of liberty or state-controlled 21 Inability to&#xD;
             participate to medical follow up for geographic&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon - Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard - Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Mont-de-Marsan</name>
      <address>
        <city>Mont-de-marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre ONCOGARD - Institut de Cancérologie du Gard</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>20004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPCA - Hôpital Privé des Côtes d'Armor</name>
      <address>
        <city>Plerin SUR MER</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie&quot;</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Courlancy Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Thonon-les-Bains</name>
      <address>
        <city>Thonon-les-Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICL Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

